Moreover, according to the pathology protocol in the different centers, our study can’t provide complete data on the biology of GH secreting adenomas and on biomarkers (such as Ki67 Li, cytokeratin granulation pattern and the expression of somatostatin receptors) that may orient the choice of second-line treatments. This evidence concerns the gene GH1 and adenoma.